Navigation Links
Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
Date:12/10/2012

nificant proportion of patients don't respond to current therapy and these treatments have dose-limiting side effects. As a result, EMA401 is being developed as a potential first-in-class oral treatment for chronic pain, including neuropathic pain, without central nervous system side effects.

Spinifex Pharmaceuticals CEO Tom McCarthy said: "Today's announcement marks another significant step in the development of EMA401 and for Spinifex. Our recent results for EMA401 in PHN served to highlight its potential as an entirely novel approach for the treatment of neuropathic pain. We look forward to completing this study in a second key indication and to moving EMA401 further towards being an important treatment for broader chronic and neuropathic pain indications."

Lead Investigator, Professor Praveen Anand, said: "The pain associated with CIPN can be extremely debilitating and may affect the quality of life of patients for years, even when the cancer is in remission. Further, CIPN symptoms are a major reason for cancer treatments to be reduced or stopped early. The use of an AT2 receptor antagonist as a treatment for neuropathic pain is a highly innovative approach and, in addition to the strong Phase 2 results already seen by the company, my own group has undertaken non-clinical work which is highly compelling. EMA401 could represent a valuable new option for patients in an area where there is a clear need for new medicines."

As described above EMA401 is an AT2 receptor antagonist. The discovery that AT2 receptor antagonists offer an innovative approach to the treatment of neuropathic and inflammatory pain was originally made by Professor Maree Smith at The University of Queensland. Having acquired the technology, Spinifex has conducted a comprehensive pre-clinical and early clinical development program on EMA401. Spinifex continues to conduct research into the role of the AT2 receptor in nociceptive, inf
'/>"/>

SOURCE Spinifex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Seahorse Bioscience Announces Asia Mito 2012 Travel Award Winners Advancing Cell Metabolism Research
2. Blue Belt Technologies Announces Golden Jubilee National Hospital Completes Initial NavioPFS Unicondylar Knee Replacement Surgery
3. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
4. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
6. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
7. OrthoAccel Technologies, Inc. Announces Appointment of New Chief Financial Officer
8. Cerecor Announces Option to Johns Hopkins Brain Science Institute DAAO Inhibitor Platform
9. Savient Announces the Election of Robert G. Savage to its Board of Directors
10. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
11. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... the availability of the ResMed Data Exchange program, ... for home medical equipment (HME) and other health ... offers timely, secure access to critical patient information. ... from ResMed,s AirView™ and U-Sleep™ patient management platforms ...
(Date:10/20/2014)...   Taiho Oncology, Inc. , a subsidiary ... ), announced that the U.S. Food and ... TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an ... treatment of refractory metastatic colorectal cancer (mCRC), and ... submission to the FDA. According to the American ...
(Date:10/20/2014)... 20, 2014 Norgine B.V. today ... low volume bowel preparation, NER1006, presented at the 79 ... of Gastroenterology (ACG), Philadelphia, PA , ... weight and co-primary endpoint of cleansing success. The study ... MOVIPREP ® in screening colonoscopy patients. [1] ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
(Date:10/20/2014)... 20, 2014 T.E.N., a technology ... announced today that William H. Murray, renowned author ... ISE® Luminary Leadership Award winner. Presented annually, the ... an outstanding leader and industry practitioner for his ... advancing the information security industry. , Formerly with ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive ... a platform to think outside the bra. She doesn’t try ... to raise awareness about women’s other lady parts. , "We ... say the color pink and everybody knows what you’re talking ... that it has not been won when it comes to ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today ... new module enables easy administration and routing of follow-up ... , This application allows users such as Therapists to ... to-do item to a specific client, categorize tasks the ... reminders for follow-ups. It's designed to enable easy ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Sit and Slim II . , The ... use Sit and Slim II because it contains Sibutramine ... weight loss product on various websites and possibly in some ... for safety reasons, can significantly increase blood pressure and/or pulse ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2
... creating a DNA fingerprinting database //of convicts. A draft providing for ... as evidence is ready and is likely to be tabled in ... is being circulated among ministries of law, home affairs and science. ... is tabled in the parliament., ,If passed, the bill will ...
... responsible for killing up to half a million Ethiopian ... condition and includes children who are 70 percent or ... height measurements., ,Malnutrition is also a major concern ... What is all the more alarming is that acute ...
... could decrease the risk of liver cancer.Researchers from Japan// ... frequency of coffee consumption among more than 60,000 people. ... they found that those who drink coffee occasionally reduced ... drinking one or more cups a day had a ...
... mother.There is no substitute to her milk’,// . ,Breast ... of WHO, UNICEF and breast feeding steering committees as ... Breastfeeding Week (Aug 1-7)’ comes to an end of weeklong ... important observations in many countries. While in some countries it ...
... appearance, their a large demand for slimming products among consumers ... also shows that slimming products in Belgium grew by 14 ... value of €29 million. , ,Despite the drive by ... the main driver of growth in slimming products in Belgium ...
... Pentagon’s Office of Naval Research are working on using ... Stress Disorder (PTSD). //, ,In this research, scientists ... suffering from PTSD to go through the similar experiences ... with the traumatic experience that had left them unable ...
Cached Medicine News:Health News:DNA Directory Under Construction For Indian Criminals ! 2Health News:With More Appearance Conscious Consumers The Need For Slimming Products Is Rapidly Rising 2
... the first and only one-bottle lens care ... conditions gas permeable contact lenses, but also ... the leading two-bottle GP lens care system. ... insertion by enveloping the lenses and creating ...
Menicon Z is a rigid gas lens with high oxygen permeability. As one of its specific characteristics, it can provide superior visual correction and show excellent performance against astigmatism....
... using sophisticated lathing techniques, intrinsically permeable polymers ... a center thickness of just 0.08 across ... powered Thinsite lenses maintain a 30% decrease ... unique design eliminates stress points to reduce ...
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Medicine Products: